BeOne Medicines (ONC) Long-Term Debt Repayments (2018 - 2026)

BeOne Medicines (ONC) has 6 years of Long-Term Debt Repayments data on file, last reported at $7.6 million in Q1 2026.

• Quarterly Long-Term Debt Repayments rose 81.28% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.1 million (up 36.41% YoY) and the FY2025 annual result came in at $35.7 million, up 27.29% from the prior year.
• Long-Term Debt Repayments fell to $7.6 million in Q1 2026 per ONC's latest filing, from $14.6 million in the prior quarter.
• Across five years, Long-Term Debt Repayments topped out at $14.6 million in Q4 2025 and bottomed at $1.5 million in Q1 2023.
• The 4-year median for Long-Term Debt Repayments is $5.2 million (2023), against an average of $6.8 million.
• Peak annual rise in Long-Term Debt Repayments reached 314.65% in 2024, while the deepest fall reached 57.92% in 2024.
• Tracing ONC's Long-Term Debt Repayments over 4 years: stood at $5.2 million in 2023, then jumped by 99.89% to $10.4 million in 2024, then jumped by 39.89% to $14.6 million in 2025, then sank by 47.73% to $7.6 million in 2026.
• Per Business Quant, the three latest ONC Long-Term Debt Repayments figures stand at $7.6 million (Q1 2026), $14.6 million (Q4 2025), and $4.3 million (Q3 2025).

Peer Comparison